Rare epilepsy

Advertisement

Jazz Paid $820 Million Upfront for a Phase 1b/2a Because the FDA Pathway Came With It

by
Jazz Paid $820 Million Upfront for a Phase 1b/2a Because the FDA Pathway Came With It

QuickDeal read/Rare Diseases/Small Molecule Jazz Paid $820 Million Upfront for a Phase 1b/2a Because the FDA Pathway Came With It Athithi Verma· 11 August 2026· 3 min read· Synopulse Jazz Pharmaceuticals will acquire privately held Actio Biosciences for $820 million upfront plus up to $500 million in approval and sales milestones, a maximum of $1.32 … Read more